Hongyan Wang PhD

Hongyan Wang PhD
Res ScientistOfc of Health Scienceswang.1375@osu.edu
302 James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-292-0672Fax: 614-293-2695
  • Experimental Therapeutics

General Research Interest

My major research interest is to understand the molecular mechanisms underlying the anti-cancer effects of small-molecule agents and microRNA; and establish their pharmacokinetic-pharmacodynamic correlation in rodent models of acute myeloid leukemia.

Research Description

We are currently performing pre-clinical testing of synthetic microRNAs with the goal of moving them into the clinical trials and eventually developing them as cancer therapeutics. A second research area is to elucidate novel mechanisms of actions of nucleoside analogs. Information from these studies will provide basis for new drug combinations for cancer therapy.

Current Publications

  • Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15(1) 242-9 1/1/2013
  • Wang H, Chiu M, Xie Z, Chiu M, Liu Z, Chen P, Liu S, Byrd JC, Muthusamy N, Garzon R, Croce CM, Marcucci G, Chan KKSynthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.Mol Pharm 9(6) 1638-44 6/4/2012
  • Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci G, Chan KKRNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.Blood 119(22) 5229-38 5/31/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu